TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS)

View full entity profile (contributions, contracts, SEC) →

Lobbying Spend

—

Filings

Firms Hired

Active Period

2012–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	6	2
2025	—	8	2
2024	—	4	1
2023	—	4	1
2022	—	5	1
2021	—	4	1
2020	—	4	1
2019	—	5	1
2018	—	4	1
2017	—	4	1
2016	—	4	1
2015	—	4	1
2014	—	5	1
2013	—	4	1
2012	—	4	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
TIBER CREEK GROUP	—	62
B HALL STRATEGIES, LLC	—	7

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	61
HOUSE OF REPRESENTATIVES	60
Executive Office of the President (EOP)	10

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	54
Medicare/Medicaid	Medicare/Medicaid	51
Trade (domestic/foreign)	Trade (domestic/foreign)	23
Pharmacy	Pharmacy	21
Budget/Appropriations	Budget/Appropriations	7
Foreign Relations	Foreign Relations	6
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	5

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1492

H.R. 1672119th Congress

Maintaining Investments in New Innovation Act

2026 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1672

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1492

H.R. 1672119th Congress

Maintaining Investments in New Innovation Act

2026 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1672

Show 21 more cited filings

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2026 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1492

H.R. 1672119th Congress

Maintaining Investments in New Innovation Act

2026 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to the One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1672

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2025 · fourth_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1492

H.R. 1672119th Congress

Maintaining Investments in New Innovation Act

2025 · fourth_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1672

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2025 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1492

H.R. 1672119th Congress

Maintaining Investments in New Innovation Act

2025 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1672

H.R. 1492119th Congress

To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

2025 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R.1672 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1492

H.R. 1672119th Congress

Maintaining Investments in New Innovation Act

2025 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to drug pricing; Issues related to One Big Beautiful Bill Act (PL 119-21); Issues related to H.R. 1492 - To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; Issues related to H.R.1672 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R.1672

H.R. 1672119th Congress

Maintaining Investments in New Innovation Act

2025 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R. 1672 - Maintaining Investments in New Innovation (MINI) Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 1672

H.R. 5547118th Congress

Maintaining Investments in New Innovation Act

2024 · fourth_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5547

S. 476118th Congress

Maintaining Investments in New Innovation Act

2024 · fourth_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 476

H.R. 5547118th Congress

Maintaining Investments in New Innovation Act

2024 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R.5547

S. 476118th Congress

Maintaining Investments in New Innovation Act

2024 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 476

H.R. 5547118th Congress

Maintaining Investments in New Innovation Act

2024 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R. 5547

S. 476118th Congress

Maintaining Investments in New Innovation Act

2024 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to the implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 476

H.R. 5547118th Congress

Maintaining Investments in New Innovation Act

2024 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: H.R.5547

S. 476118th Congress

Maintaining Investments in New Innovation Act

2024 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 476

S. 476118th Congress

Maintaining Investments in New Innovation Act

2023 · fourth_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 476

S. 476118th Congress

Maintaining Investments in New Innovation Act

2023 · third_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 476

S. 476118th Congress

Maintaining Investments in New Innovation Act

2023 · second_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476, Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 476

S. 476118th Congress

Maintaining Investments in New Innovation Act

2023 · first_quarter · Firm: TIBER CREEK GROUP

Open original LDA filing ↗

Cited source text and reported amounts

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D rebates; S. 476, Maintaining Investments in New Innovation Act.

Client expense: — · Firm income: $60,000

Matched citations: S. 476

Source: Senate LDA

TIBER CREEK HEALTH STRATEGIES, INC. (ON BEHALF OF NOVARTIS) — Lobbying Disclosure | Poliscope